FAETH THERAPEUTICS Insider Buy: Karen Vousden’s 25,000 Options Boost Confidence in Oncology Growth
FAETH Therapeutics insider buys 25,000 options, signaling long‑term confidence amid 293% YTD rally and clinical‑stage optimism.
3 minutes to read
FAETH THERAPEUTICS INC
FAETH THERAPEUTICS: Khosla Ventures & Insider Buying Signal Optimism Amid Volatile Oncotherapy Valuation
FAETH THERAPEUTICS sees Khosla Ventures stake and insider buys signal confidence, yet its early‑stage oncology platform remains highly speculative with a negative P/E and limited market cap. This article breaks down the implications, market sentimen…
4 minutes to read
Faeth CFO’s Insider Buying Surge Signals Strong Investor Confidence and Upside
Faeth Therapeutics CFO’s bulk buying shows insider confidence in a promising CAR‑T pipeline and strong upside potential—investors should watch this trend.
4 minutes to read